Avichai Eres, MD
Interventional Cardiology · Lexington, KYNPI 1740255314
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $542,117 of the $616,218 with a category attached, or 88.0%. 54 manufacturers reported payments, led by Novo Nordisk at 27.6% of the total. Among interventional cardiology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,545 payments — averaging $398.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$170K
- Johnson & Johnson$124K
- Bayer$67K
- Esperion Therapeutics, Inc.$64K
- Boehringer Ingelheim$59K
- Amarin Pharma, Inc.$33K
- plus $98K from 48 others
Across 6 payments — averaging $77.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$464
What the payments were for
- Consulting fees$5,0901%
- Speaking & faculty fees$542,11788%
- Travel & lodging$42,4607%
- Food & beverage$26,3484%
- Education$1280%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$121,270
- Ozempic$96,207
- JARDIANCE$72,321
- Kerendia$65,897
- NEXLIZET$63,309
- NEXLETOL$63,309
- Vascepa$32,082
- PRALUENT$21,788
- ENTRESTO$20,815
- NORTHERA$12,756
- FARXIGA$3,000
- LOKELMA$2,411
- LifeVest$1,500
- PRADAXA$1,040
- Resolute$321
- ATRICLIP LAA EXCLUSION SYSTEM$159
- Hillrom - Carnation Ambulatory Monitor$132
- Pulmonx Endobronchial Valve EBV$128
- Confirm Rx$121
- MULTAQ$108
How this compares
$616,218 in reported general payments places this provider in the 95th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 968 | $1,180,404 |
| OzempicSemaglutide | 534 | $673,710 |
| JardianceEmpagliflozin | 458 | $551,723 |
| EntrestoSacubitril/Valsartan | 382 | $518,669 |
| KerendiaFinerenone | 252 | $325,295 |
| EliquisApixaban | 254 | $304,713 |
| Repatha SureclickEvolocumab | 262 | $267,543 |
| FarxigaDapagliflozin Propanediol | 226 | $231,414 |
| NexlizetBempedoic Acid/Ezetimibe | 218 | $178,022 |
| VascepaIcosapent Ethyl | 178 | $144,253 |
| BrilintaTicagrelor | 97 | $97,116 |
| MultaqDronedarone Hcl | 50 | $85,618 |
| Praluent PenAlirocumab | 66 | $60,761 |
| RybelsusSemaglutide | 35 | $57,584 |
| WegovySemaglutide | 35 | $50,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $124,394 | $1,180,404968 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $170,277 | $781,659604 claims |
| Boehringer IngelheimJardiance | $59,026 | $551,723458 claims |
| NovartisEntresto | $23,278 | $518,669382 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $6,421 | $342,111341 claims |
| BayerKerendia | $66,968 | $325,295252 claims |
| PfizerEliquis | $764 | $304,713254 claims |
| Esperion Therapeutics, Inc.Nexlizet | $64,260 | $178,022218 claims |
| Sanofi-aventis U.S. LLCMultaq | $22,694 | $85,61850 claims |
| Lilly USA, LLCMounjaro | $18,840 | $49,06237 claims |
| MerckVerquvo | $770 | $29,76336 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $46 | $27,09454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Lexington
- Steve LinLexington$362K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Armaghan SoomroLexington$117K
- Adrian MesserliLexington$41K
- Hussam HamdallaLexington$24K
- Henry Charles RichmondLexington$20K
- Michael ShihLexington$20K
- Mubashir QaziLexington$18K
- Michael RukavinaLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.